Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials

Journal of Rheumatology

Volumn 39, Issue 7, 2012, Pages 1450-1457

  Strand, Vibeke ^a   Khanna, Dinesh ^b   Singh, Jasvinder A ^c   Forsythe, Anna ^d   Edwards, N Lawrence ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Savient Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Gout; Outcomes research; Patient perspective; Pegloticase; Treatment

Indexed keywords

FEXOFENADINE; HYDROCORTISONE; PARACETAMOL; PEGLOTICASE; PLACEBO; URIC ACID;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; GOUT; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFRACTORY CHRONIC GOUT; SHORT FORM 36; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PHYSICAL FITNESS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URATE OXIDASE; URIC ACID; YOUNG ADULT;

EID: 84863519098     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111375     Document Type: Article

References (34)

1. Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.
3. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008;67:1310-6.
4. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54.
5. Alvarez-Hernández E, Peláez-Ballestas I, Vázquez-Mellado J, Terán-Estrada L, Bernard-Medina AG, Espinoza J, et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 2008;59:665-9. (Pubitemid 351679541)
6. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68. (Pubitemid 350186186)
7. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8. (Pubitemid 47122319)
8. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beittes AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;15:356-60. (Pubitemid 34856121)
9. Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. Two randomized controlled trials. JAMA 2011;306:711-20.
10. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective. J Rheumatol 1993;20:557-60. (Pubitemid 23102493)
11. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): A literature review and directions for future research. Curr Opin Rheumatol 2002;14:109-14. (Pubitemid 34185291)
12. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: A review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78. (Pubitemid 36077790)
13. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:506-14. Erratum in: Arthritis Rheum 2000;43:1345. (Pubitemid 30394940)
14. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32:583-9. (Pubitemid 40524688)
15. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: Impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
16. Strand V, Kelman A. Outcome measures in osteoarthritis: Randomized controlled trials. Curr Rheumatol Rep 2004;6:20-30.
17. Strand V, Petri M, Buyon J, Joh T, Freimuth W, Sigler L, et al. Systemic lupus erythematosus impacts all domains of health-related quality of life (HRQOL): Baseline results from five randomized controlled trials [abstract]. Ann Rheum Dis 2007;66:SII:482.
18. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: An update. Ann Acad Med Singapore 2007;36:115-22. (Pubitemid 46640263)
19. Strand V, Sharp V, Koenig A, Park G, Shi Y, Wang B, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012 Jan 17 [E-pub ahead of print].
20. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40. (Pubitemid 40676492)
21. Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 2009;36:2330-4.
22. Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of chronic gout. Qual Life Res 2008;17:815-22.
23. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001;45:384-91. (Pubitemid 32738745)
24. Strand V. Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trials. Clin Exp Rheumatol 2004;22:S57-64. (Pubitemid 39328356)
25. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87. (Pubitemid 30452465)
26. Strand V, Crawford B. Improvement in health-related quality of life in patients with systemic lupus erythematosus following sustained reductions in anti-dsDNA antibodies. Exp Rev Pharmacoecon Outcomes Res 2005;5:317-26. (Pubitemid 40894969)
27. Ara R, Brazier J. Predicting the Short Form-6D Preference-Based Index using the eight mean Short Form-36 Health Dimension scores: Estimating preference-based health-related utilities when patient level data are not available. Value Health 2009;12:346-53.
28. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131-43.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
30. Ware JE Jr, Kosinski M, Dewey JE. How to score Version 2 of the SF-36 Health Survey. Lincoln, RI: QualityMetric Inc.; 2000.
31. Krystexxa prescribing information. East Brunswick, NJ: Savient Pharmaceuticals Inc. 2010. [Internet. Accessed March 22, 2012.] Available from: http://www.krystexxa.com
32. Strand V, Singh JA, Sundy J, Schumacher HR, Becker M, Edwards NL. Health-related quality-of-life (HRQOL) of patients with refractory gout and US Veterans Administration patients with gout and comorbidities (VA-Gout) is poor and comparable to that in other severe chronic conditions [abstract]. Arthritis Rheum 2008;58 Suppl:S177.
33. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14-8. (Pubitemid 46657507)
34. Fleishman JA, Cohen JW, Manning WG, Kosinski M. Using the SF-12 health status measure to improve predictions of medical expenditures. Med Care 2006;44:I54-63. (Pubitemid 43755413)